Subscribe Subscribe   Find us on Twitter Follow POL on Twitter  



Newsweek's Gasparino on Vioxx

Consumers, he says, are going to be the biggest losers in the litigation:

I'm here to tell you that the Vioxx case is plenty more complicated that Lanier lets on, and unfortunately for all of us, its impact will be felt by far more people than the 7,000 Merck employees who will soon lose their jobs. ...

Which brings me to my larger point: when are juries going to take into account the economic costs of their action? I'll be the first to admit that sometimes it's easier to hate corporate America even more than all those loathsome lawyers (or for that matter, nerdy journalists). I, for one, have made a career exposing the duplicity and corruption of Wall Street's top firms, and I'll be the first to side with any plaintiff that has a clear-cut case of fraud.

But such black-and-white cases, at least in my experience, have been rare....

He even quotes our own Jim Copland:

James Copland, director of the Center for Legal Policy at the Manhattan Institute who has studied the history of jury awards, says the final liability "almost always blows past the initial estimates."



Rafael Mangual
Project Manager,
Legal Policy

Manhattan Institute


Published by the Manhattan Institute

The Manhattan Insitute's Center for Legal Policy.